<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pathogens-09-00519-t005" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pathogens-09-00519-t005_Table 5</object-id>
 <label>Table 5</label>
 <caption>
  <p>A summary of vaccine and drug candidates being used or under consideration (phase I clinical trials) for the prevention/treatment of COVID-19.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine/Drug Candidates</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developer</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Remarks</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Vaccines candidates</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-1273</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderna/NIAID</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1
     <break/>(NCT04283461)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials started at Kaiser Permanente Washington Health Research Institute in Seattle, USA</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad5-nCov</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CanSino Biological Inc.
     <break/>and Beijing Institute of Biotechnology
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1
     <break/>(ChiCTR2000030906)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials recently started at Tongji Hospital in Wuhan, China</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INO-4800</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inovio Pharmaceuticals</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I (NCT04336410)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA plasmid encoding S protein delivered by electroporation</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LV-SMENP-DC</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I (NCT04276896)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cells modified with lentiviral vector and expressing synthetic minigene based on domains of selected viral proteins</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathogen-specific aAPC</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I (NCT04299724)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artificial antigen-presenting cells (aAPCs) modified with lentiviral vector and expressing synthetic minigene based on domains of selected viral proteins</td>
   </tr>
   <tr>
    <td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
     <bold>Drug candidates</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favilavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hisun Pharmaceutical, China</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved by NMPA, China</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of RNA-dependent RNA polymerase of SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroxychloroquine and azithromycin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials are under progress</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both have shown in vitro activity against SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gilead Sciences, USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trials are under progress</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed for treatment of Ebola virus infection</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir + Ritonavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AbbVie, USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Further research is under process</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developed to treat HIV-1 infections</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
